Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3HP vs 9H for LTBI in Poorly Controlled Diabetes
NCT06874725Phase 4Active, not recruiting
- Sponsor
- Taichung Veterans General Hospital
- Start
- Apr 2018
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifapentine in latent tuberculosis infection (LTBI), sponsored by Taichung Veterans General Hospital. Primary endpoint: Brain-Derived Neurotrophic Factor at 9 months. Started Apr 2018; status: active, not recruiting.
02
Drugs
rifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT06874725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874725.